glp 1 and thyroid issues GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges GLP-1 Therapy with Thyroid Conditions

Phase 3 Update: TRIUMPH-4 Results Preliminary data from the ongoing Phase 3 TRIUMPH-4 trial (68 weeks) shows higher numbers than Phase 2: 12mg dose: 28.7% average weight loss (~71 lbs / 32 kg) 9mg dose: 26.4% average weight loss (~64 lbs / 29 kg) Knee osteoarthritis pain: 76% reduction (significant quality-of-life improvement) Blood pressure: Average reduction of 14 mmHg Full Phase 3 results across the TRIUMPH program (obesity, diabetes, cardiovascular outcomes, kidney outcomes) are expected throughout 2026

Support the Signals That Shape Your Weight* Akkermansia muciniphila and clinically studied postbiotic BPL1 come together for the first time in this unique probiotic + postbiotic formula to deliver targeted support to the gutmetabolic connection for healthy weight management.* Akkermansia aids your bodys natural GLP-1 production, while clinically studied postbiotic BPL1 helps reduce abdominal fat and support healthy blood sugar metabolism.* Designed to Survive Each capsule delivers 500 million AFUs live Akkermansia muciniphila and delays release for survivability through stomach acid

Predictors of weight variation and weight gain in peri- and post-menopausal women

the chemical regulates how food moves through the digestive tract

These results are often more pronounced than those achieved through diet and exercise alone, especially in individuals who are obese or have been struggling with weight loss for a long time

Oral GLP-1 drugs like orforglipron may eventually provide pill-based alternatives that actually work